EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Fluid Biomarkers of Disease Burden and Cognitive Dysfunction in Progressive Supranuclear Palsy

Roxane Dilcher iD, Charles B Malpas, Stuart J McDonald iD, William T O'Brien, Craig Despott, Kelly L Bertram, Matthew P Pase iD, Lukas Frontzkowski, Meng Law, Terence J O'Brien, Lucy Vivash iD

Annals of Clinical and Translational Neurology · 2026-07 · 13 (7) · 1422-1432

DOI: 10.1002/acn3.70327 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, online erschienen am 28.01.2026. Verfasst von Roxane Dilcher und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosciences, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Supranuclear Palsy, Progressive, tau Proteins, Cognitive Dysfunction, Neurofilament Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Brain Foundation, National Health and Medical Research Council, Medical Research Future Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Identifying objective biomarkers for progressive supranuclear palsy (PSP) is crucial to improving diagnosis and establishing clinical trial and treatment endpoints. This study evaluated fluid biomarkers in PSP versus controls and their associations with regional 18 F‐PI‐2620 tau‐PET, clinical, and cognitive outcomes.

Methods

Twenty‐four PSP patients and 11 age‐ and sex‐matched control subjects underwent Cerebrospinal fluid (CSF) and plasma assays of neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), and total tau (t‐tau) using SIMOA. Ratios (NfL/t‐tau, GFAP/t‐tau, GFAP/NfL) were calculated. Tau burden was quantified using PI‐2620 distribution volume ratio (DVR). Group comparisons and associations with tau‐PET, MRI, and cognition were tested using Wilcoxon tests, ROC analyses, and age‐ and sex‐adjusted linear models.

Results

PSP patients showed elevated NfL, GFAP levels, and higher NfL/t‐tau and GFAP/t‐tau ratios in CSF and plasma. CSF NfL/t‐tau best discriminated PSP from control subjects (AUC = 0.99, 95% CI [0.97–1.00]; optimal cut‐off: > 10), followed by CSF GFAP/t‐tau (AUC = 0.89, 95% CI [0.76–1.00]; > 104) and plasma NfL/t‐tau (AUC = 0.80, 95% CI [0.63–0.96]; 5.1). Plasma NfL/t‐tau correlated with tau‐PET DVR in the putamen ( β = 0.63; 95% CI [0.15–1.11]; p < 0.01) and pallidum ( β = 0.54, 95% CI [0.07–1.02]; p < 0.01) and predicted disease severity ( β = 0.61, 95% CI [0.19, 1.04]; p = 0.007) and processing speed ( β = 0.66, 95% CI [0.22, 1.10]; p = 0.006), explaining 35% and 33% of variance, respectively. Frontal MRI volume modestly improved prediction of processing speed (Δ R 2 adj = 0.23, p = 0.01), whereas tau‐PET did not.

Interpretation

Plasma NfL/t‐tau correlates with regional tau, disease severity, and cognition. Fluid biomarkers, complemented by PET and MRI, may support multimodal PSP diagnosis, monitoring, and trial stratification. Trial Registration Australian New Zealand Clinical Trials Registry: ACTRN12620001254987

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Supranuclear Palsy, Progressivetau ProteinsCognitive DysfunctionNeurofilament ProteinsGlial Fibrillary Acidic ProteinHumansFemaleMaleBiomarkersAgedPositron-Emission TomographyMiddle AgedMagnetic Resonance Imaging

Stichwörter der Autor:innen

biomarkersprogressive supranuclear palsytautau‐PET

Substanzen

tau ProteinsBiomarkersNeurofilament ProteinsGlial Fibrillary Acidic Proteinneurofilament protein LGFAP protein, humanMAPT protein, human

Autor:innen und Institutionen

  • Department of Neurosciences, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia.
  • Department of Medicine, Royal Melbourne Hospital, The University of Melbourne, Melbourne, Victoria, Australia.
  • Melbourne School of Psychological Sciences, The University of Melbourne, Melbourne, Victoria, Australia.
  • Department of Neurology, Alfred Hospital, Melbourne, Victoria, Australia.
  • Department of Nuclear Medicine, Alfred Health, Melbourne, Victoria, Australia.
  • School of Psychological Sciences, Turner Institute for Brain and Mental Health, Monash University, Clayton, Victoria, Australia.

ORCID-Profile: Roxane Dilcher, Stuart J McDonald, Matthew P Pase, Lucy Vivash

Förderung

  • Brain Foundation
  • National Health and Medical Research Council
  • Medical Research Future Fund
  • Monash University
  • Alzheimer's Association

Zitieren

APA

Dilcher, R., Malpas, C. B., McDonald, S. J., O'Brien, W. T., Despott, C., Bertram, K. L., Pase, M. P., Frontzkowski, L., Law, M., O'Brien, T. J., & Vivash, L. (2026). Fluid Biomarkers of Disease Burden and Cognitive Dysfunction in Progressive Supranuclear Palsy. Annals of Clinical and Translational Neurology, 13(7), 1422-1432. https://doi.org/10.1002/acn3.70327

Vancouver

Dilcher R, Malpas CB, McDonald SJ, O'Brien WT, Despott C, Bertram KL, et al. Fluid Biomarkers of Disease Burden and Cognitive Dysfunction in Progressive Supranuclear Palsy. Annals of Clinical and Translational Neurology. 2026;13(7):1422-1432. doi:10.1002/acn3.70327

BibTeX
@article{Dilcher2026,
  author = {Dilcher, Roxane and Malpas, Charles B and McDonald, Stuart J and O'Brien, William T and Despott, Craig and Bertram, Kelly L and Pase, Matthew P and Frontzkowski, Lukas and Law, Meng and O'Brien, Terence J and Vivash, Lucy},
  title = {Fluid Biomarkers of Disease Burden and Cognitive Dysfunction in Progressive Supranuclear Palsy},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2026},
  volume = {13},
  number = {7},
  pages = {1422--1432},
  doi = {10.1002/acn3.70327}
}
Kostenlos starten →